Literature DB >> 2567549

Bone marrow analysis of the myelodysplastic syndromes: histological and immunohistochemical features related to the evolution of overt leukemia.

M Kitagawa1, R Kamiyama, T Takemura, T Kasuga.   

Abstract

Bone marrow trephines from 31 patients with an initial diagnosis of myelodysplastic syndromes (MDS) were examined and analyzed histologically and immunohistochemically. In those cases terminating in overt leukemia (6/31, 19%), the number of bone marrow mast cells was significantly reduced, compared with those which did not evolve to overt leukemia. The bone marrow lymphoid cells that may participate in immunosurveillance against the proliferation of blast cells were also significantly reduced in cases terminating in overt leukemia. However, S-100 protein-positive cells, which include histiocytes and suppressor T-cells, were increased in cases terminating in overt leukemia. The results indicated that examination of the bone marrow to determine the proportions of mast cells and lymphoid cells which may be involved in host defense systems may be useful in predicting the evolution to overt leukemia in MDS. In the present series, patients with a hypocellular marrow (5/31, 16%) did not progress to overt leukemia and had a significantly lower bone marrow reticulin content, a significantly lower megakaryocyte count, a relatively higher mast cell count and a significantly higher lymphoid cell count than those with a normocellular or hypercellular marrow. These findings may reflect the initial features of MDS or, possibly, that hypocellular MDS is an independent entity with a low potential for blastic proliferation.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2567549     DOI: 10.1007/BF02899064

Source DB:  PubMed          Journal:  Virchows Arch B Cell Pathol Incl Mol Pathol        ISSN: 0340-6075


  9 in total

1.  Dysmegakaryopoiesis in myelodysplastic syndromes (MDS): an immunomorphometric study of bone marrow trephine biopsy specimens.

Authors:  J Thiele; H Quitmann; S Wagner; R Fischer
Journal:  J Clin Pathol       Date:  1991-04       Impact factor: 3.411

2.  Hypocellular myelodysplastic syndromes: clinical and biological significance.

Authors:  Dragomir Marisavljevic; Vesna Cemerikic; Zoran Rolovic; Darinka Boskovic; Milica Colovic
Journal:  Med Oncol       Date:  2005       Impact factor: 3.064

Review 3.  Megakaryocytopoiesis in haematological disorders: diagnostic features of bone marrow biopsies. An overview.

Authors:  J Thiele; R Fischer
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1991

4.  Prognostic relevance of histological findings on bone marrow biopsy in myelodysplastic syndromes.

Authors:  G Lambertenghi-Deliliers; C Annaloro; A Oriani; D Soligo; E Pozzoli; E E Polli
Journal:  Ann Hematol       Date:  1993-02       Impact factor: 3.673

5.  p53 expression in myeloid cells of myelodysplastic syndromes. Association with evolution of overt leukemia.

Authors:  M Kitagawa; S Yoshida; T Kuwata; T Tanizawa; R Kamiyama
Journal:  Am J Pathol       Date:  1994-08       Impact factor: 4.307

6.  Hypoplastic myelodysplastic syndrome: incidence, morphology, cytogenetics, and prognosis.

Authors:  H Maschek; V Kaloutsi; M Rodriguez-Kaiser; M Werner; H Choritz; K Mainzer; M Dietzfelbinger; A Georgii
Journal:  Ann Hematol       Date:  1993-03       Impact factor: 3.673

7.  Bone marrow lymphocyte subsets in myelodysplastic syndromes.

Authors:  W Hilbe; W Eisterer; C Schmid; I Starz; H Silly; C Duba; C Ludescher; J Thaler
Journal:  J Clin Pathol       Date:  1994-06       Impact factor: 3.411

8.  Myelodysplastic syndromes: immunohistochemical and morphometric evaluation of proliferative activity in erythropoiesis and endoreduplicative capacity of megakaryocytes.

Authors:  J Thiele; I Hoffmann; H P Bertsch; R Fischer
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

Review 9.  Bone marrow niches in myeloid neoplasms.

Authors:  Masanobu Kitagawa; Morito Kurata; Iichiroh Onishi; Kouhei Yamamoto
Journal:  Pathol Int       Date:  2019-11-10       Impact factor: 2.534

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.